Publications
Detailed Information
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.date.accessioned | 2021-01-31T11:05:58Z | - |
dc.date.available | 2021-01-31T11:05:58Z | - |
dc.date.created | 2020-12-17 | - |
dc.date.created | 2020-12-17 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.74 No.3, pp.447-455 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 119264 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173022 | - |
dc.description.abstract | To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC). This single-arm phase II study was conducted at three institutions in Korea. Patients with MCRC refractory to fluoropyrimidine, oxaliplatin and irinotecan were enrolled. Gemcitabine 800 mg/m(2) was administered intravenously on days 1, 8 and 15. UFT 200 mg/m(2)/day was taken orally in three divided doses on days 1-21. Cycles were repeated every 4 weeks, and tumor evaluation was carried out every 8 weeks. The primary endpoint of this study was 8-week progression-free survival (PFS) rate. Forty-one patients were enrolled. Fourteen patients received gemcitabine/UFT as a third-line treatment and 37 patients as a fourth-line or later-line therapy. Toxicities were easily manageable, and non-hematologic toxicities of a parts per thousand yengrade 3 were rare. The most common toxicity of a parts per thousand yengrade 3 was neutropenia (20.0 %). One patient showed partial response (response rate, 2.4 %) and 14 (34.1 %) showed stable disease. The 8-week PFS rate was 42.3 %. The median PFS was 1.7 months [95 % confidence interval (CI) 1.6-1.8 months], and the median overall survival was 9.2 months (95 % CI 5.8-12.6 months). Overall efficacy of gemcitabine/UFT in refractory MCRC was unsatisfactory. However, we could find a minor proportion of patients who showed prolonged tumor stabilization to gemcitabine/UFT. Further studies are warranted to identify a patient subgroup that might have benefits from gemcitabine/UFT therapy. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00280-014-2515-8 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.identifier.wosid | 000341180200002 | - |
dc.identifier.scopusid | 2-s2.0-84907598512 | - |
dc.citation.endpage | 455 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 447 | - |
dc.citation.volume | 74 | - |
dc.identifier.sci | 000341180200002 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | INTRAVENOUS FLUOROURACIL | - |
dc.subject.keywordPlus | ORAL CAPECITABINE | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | BENEFIT | - |
dc.subject.keywordPlus | KRAS | - |
dc.subject.keywordAuthor | Metastatic colorectal cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Refractory | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | UFT | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.